Development of Monoclonal Antibody-Based Immunoassays for Quantification and Rapid Assessment of Dihydroartemisinin Contents in Antimalarial Drugs.
Xiangxue Ning,Weizhi Li,Mian Wang,Suqin Guo,Guiyu Tan,Baomin Wang,Liwang Cui
DOI: https://doi.org/10.1016/j.jpba.2018.06.051
IF: 3.571
2018-01-01
Journal of Pharmaceutical and Biomedical Analysis
Abstract:Dihydroartemisinin (DHA) is one of the artemisinin derivatives widely used in artemisinin-based combination therapies (ACTs) for malaria treatment. The availability of a point-of-care device for estimation of DHA quantity would allow a quick quality assessment of the DHA-containing drugs. In this study, 9-O-succinylartemisinin was obtained from microbial fermentation of artemisinin, which was hydrogenated to 9-O-succinyldihydroartemisinin as the hapten for DHA. A monoclonal antibody (mAb), designated as 2G(1) 1G(4), was identified after screening the hybridoma library, which showed 52.3% cross reactivity to artemisinin, but low or no cross reactivity to artesunate, artemether, and several ACTs partner drugs. Based on this mAb, a highly-sensitive, indirect competitive enzyme-linked immunosorbent assay was designed, which showed 50% inhibition concentration of DHA at 1.16 ng/mL, a working range of 0.26-4.87 ng/mL, and limit of detection of 0.18 ng/mL. In addition, a colloidal gold-based lateral flow immunoassay (dipstick) was developed with an indicator range (indicating sensitivity) of 50-100 ng/mL. This dipstick was evaluated for determination of DHA contents in commercial drugs and the results were highly agreeable with those determined by high-performance liquid chromatography. (C) 2018 Elsevier B.V. All rights reserved.